Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pamvatamig - Merus

Next Previous
Drug Profile

Pamvatamig - Merus

Alternative Names: EGFR x c-MET Biclonics®; MCLA-129

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merus
  • Developer Betta Pharmaceuticals Co Ltd; Merus
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Mar 2025 Betta Pharmaceuticals plans a phase II trial for Non small cell lung cancer (Monotherapy, Second line therapy or greater, Late stage disease, Metastatic disease, Unresectable/Inoperable) in China (IV, Infusion) in March 2025 (NCT06885840)
  • 03 Jun 2024 Updated efficacy and adverse event data from a phase I/II trial in Solid tumours was released by Merus
  • 31 May 2024 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top